INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2023

A scoping review found oral curcumin trials suggest clinical benefits in metabolic and musculoskeletal disorders, but show mixed results in other diseases.

A scoping review evaluated 389 citations from human clinical trials investigating the effects of oral curcumin on disease outcomes. Nearly half the citations focused on obesity-associated metabolic disorders (29%) or musculoskeletal disorders (17%), with beneficial effects on clinical outcomes and/or biomarkers reported in 75% of these studies (77% of which were double-blind randomized placebo-controlled trials). Trials on neurocognitive (11%), gastrointestinal (10%), or cancer (9%) categories were fewer and reported mixed results depending on study quality and condition. The authors noted the need for systematic evaluation of diverse formulations and doses in larger trials.

Study type
Scoping review of clinical trials
Who was studied
389 human clinical trial citations (selected from 9,528 initial citations)
What was measured
Effects of oral curcumin supplementation on human disease outcomes and biomarkers

THE PAPER

Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials.

Panknin TM, Howe CL, Hauer M, Bucchireddigari B, Rossi AM, Funk JL. Int J Mol Sci, 2023.

PubMed 36901908 ↗DOI 10.1002/mnfr.202000977 ↗

CancerGut & microbiomeWeight & appetiteBrain & moodBones & musclesOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.